This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 10 of 19 for:    parp inhibitor ovarian | Recruiting, Not yet recruiting, Available Studies

Response to PARP Inhibitor Predicted by the RAD51 Assay (REPAIR)

This study is not yet open for participant recruitment.
See Contacts and Locations
Verified June 2017 by J.A. Gietema, University Medical Center Groningen
Sponsor:
Collaborators:
AbbVie
Dutch Cancer Society
Information provided by (Responsible Party):
J.A. Gietema, University Medical Center Groningen
ClinicalTrials.gov Identifier:
NCT03044795
First received: February 2, 2017
Last updated: June 1, 2017
Last verified: June 2017
  Purpose
In tumors with a defect in the homologous recombination (HR) pathway, double-strand break repair is partly impaired. Patients with HR deficient tumors benefit from therapies that induce DNA lesions requiring HR for repair. These therapies include platinum compounds and inhibitors of the enzyme PARP-1. At this moment, selection for PARP inhibitor treatment relies on detection of germ-line or somatic mutations in the HR pathway genes BRCA1 or BRCA2. However, not all HR deficient tumors have a BRCA gene mutation, the BRCA genes can also be silenced by promoter methylation. Moreover, the HR pathway can be defective due to mutations in other HR genes. In addition, the presence of a BRCA gene mutation does not guarantee defective HR since mutations in other genes (e.g. TP53BP1) can restore HR despite the presence of a BRCA1 mutation. Since all patients with tumors that are HR deficient may benefit from PARP inhibition, better tools are required to identify these patients. Recently, a functional ex vivo test for HR deficiency (the RAD51 assay) became available for clinical use. The RAD51 assay can identify patients with functional defects in HR-repair and may predict which cancer patients are likely to benefit from PARP inhibition. The purpose of this study is to investigate whether the RAD51 assay can select patients who will benefit from treatment with the PARP-inhibitor veliparib.

Condition Intervention Phase
Cancer Drug: Veliparib Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study With PARP Inhibitor Veliparib (ABT-888) in Patients With Increased Risk of Homologous Recombination Deficiency to Determine the Value of an (Ex-vivo) RAD51 Assay as a Biomarker

Further study details as provided by J.A. Gietema, University Medical Center Groningen:

Primary Outcome Measures:
  • Part A: determine the value of the RAD51 assay in predicting response to veliparib [ Time Frame: 8 weeks ]
    To determine the value of the RAD51 assay in predicting response to veliparib at eight weeks in patients with a high risk of HR deficiency.

  • Part B: determine response to veliparib at eight weeks in novel patient groups with HR deficient tumors a [ Time Frame: 8 weeks ]
    To determine response to veliparib at eight weeks in novel patient groups with HR deficient tumors as assessed by the RAD51 assay.


Estimated Enrollment: 100
Anticipated Study Start Date: August 2017
Estimated Study Completion Date: August 2020
Estimated Primary Completion Date: August 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Part A
Patients with TNBC, platinum sensitive high grade serous ovarian cancer or BRCA-mutated (non-)breast and (non-)ovarian cancer will be included prior to the RAD51 assay and treated with veliparib irrespective of the assay result. All patients, including TNBC patients, will receive veliparib monotherapy until at least the first tumor assessment after 8 weeks of treatment.
Drug: Veliparib
Subjects in part A and part B will all start treatment with oral veliparib monotherapy twice a day. Patients will receive oral veliparib BID on days 1- 21, q3 weeks. All subjects will start with veliparib 300 mg, if the subject tolerates 300 mg BID for 2 weeks, veliparib may be increased to 400 mg BID at the investigator's discretion. Subjects will self-administer the morning dose and the evening dose of veliparib approximately 12 hours after the morning dose with or without food. ANC must be above 1.5 × 109/L in order to commence a new cycle.
Experimental: Part B
Only patients with a RAD51 assay HR deficiency will be included. First there will be a pre-screening procedure followed by a tumor lesion biopsy on which the RAD51 assay will be performed. In case of a RAD51 assay indicating HR proficiency, patients will not be eligible for treatment in this study and cannot be included. Patients with a RAD51 assay indicating HR deficiency will be included. Eligible patients will be treated with veliparib monotherapy until at least the first tumor assessment after 8 weeks of treatment. In case of 0/15 patients within one patient subgroup having RAD51 tests showing HR-deficiency inclusion for this sub-group will be closed.
Drug: Veliparib
Subjects in part A and part B will all start treatment with oral veliparib monotherapy twice a day. Patients will receive oral veliparib BID on days 1- 21, q3 weeks. All subjects will start with veliparib 300 mg, if the subject tolerates 300 mg BID for 2 weeks, veliparib may be increased to 400 mg BID at the investigator's discretion. Subjects will self-administer the morning dose and the evening dose of veliparib approximately 12 hours after the morning dose with or without food. ANC must be above 1.5 × 109/L in order to commence a new cycle.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Part A

  1. ≥ 18 years of age.
  2. Histologically or cytologically confirmed malignancy that is metastatic or unresectable. Subjects must have either:

    1. Non-rapidly progressive disease. This means not requiring initiation of chemotherapy (within 8 weeks), based on clinician's evaluation.
    2. No effective standard of care options.
  3. Subjects must have triple negative breast cancer (maximum 10% ER expression), platinum sensitive (≥ 6 months since last platinum containing therapy) high grade serous ovarian cancer or BRCA1/2 mutated (non-)breast and (non-)ovarian cancer.
  4. The subject has had a maximum of 3 prior DNA damaging agents or cytotoxic chemotherapy treatments (prior therapies with biologic agents including, IL-2, interferon, vaccines, immunostimulating agents, immune checkpoint inhibitors and signal transduction inhibitors are allowed and do not count as a cytotoxic chemotherapy treatment line). Chemotherapy received as adjuvant therapy will not be considered as prior chemotherapy when administered at least 1 year before advanced disease has been detected.
  5. Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 to 1.
  6. Adequate hematologic, renal and hepatic function as follows:

    • Absolute Neutrophil Count (ANC) ≥ 1500/μL.
    • Platelet ≥ 100,000/μL.
    • Hemoglobin ≥ 5.6 mmol/L.
    • Serum creatinine ≤ 1.5 × upper normal limit of institution's normal range OR creatinine clearance ≥ 50 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal.
    • Bilirubin ≤ 1.5 × the upper normal limit of institution's normal range.
    • Aspartate Aminotransferase (AST) and Alanine Transaminase (ALT ≤ 2.5 ) x the upper normal limit of institution's normal range. For subjects with liver metastases, AST and ALT < 5 x the upper normal limit of institution's normal range.
    • APTT must be ≤ 1.5 × upper normal limit of institution's normal range and International Normalized Ratio (INR) < 1.5 for subjects not on anticoagulant therapy. Subjects on anticoagulant (such as Coumadin) will have PTT and INR as determined by the investigator.
    • Serum pregnancy test for women of childbearing potential, including women who have had a tubal ligation; childbearing potential is defined as not having undergone surgical sterilization, hysterectomy, and/or bilateral oophorectomy, or not being postmenopausal (≥ 12 months of amenorrhea).
  7. Females of childbearing potential and men must agree to use adequate contraception (one of the following listed below) prior to study entry, for the duration of study participation and up to 90 days following completion of therapy.
  8. Measurable disease, as defined by standard RECIST v1.1 or GCIG guidelines using ca-125 in ovarian cancer. Previously irradiated lesions should not be counted as target lesions.
  9. Metastatic or locally advanced lesion(s) of which a histological biopsy can safely be obtained according to standard clinical care procedures. Boney lesions are not acceptable as biopsy site.
  10. Capable of understanding and complying with parameters as outlined in the protocol and able to sign and date the informed consent, approved by an Independent Ethics Committee (IEC) prior to the initiation of any screening or study-specific procedures.

Part B

  1. ≥ 18 years of age.
  2. Histologically or cytologically confirmed malignancy that is metastatic or unresectable. Subjects must have either:

    1. Non-rapidly progressive disease. This means not requiring initiation of chemotherapy (within 8 weeks), based on clinician's evaluation.
    2. No effective standard of care options.
  3. Subjects with an intermediate risk of HR deficiency: head and neck cancer, non-small cell lung cancer, ER+/Grade III breast cancer, gastro-intestinal cancer, bladder cancer, ovarian cancer (not platinum sensitive high grade serous, these are eligible for part A), prostate cancer and endometrial cancer, non-small cell lung cancer (squamous histology only) with defective HR as assessed by the (ex-vivo) RAD51 assay.
  4. The subject has received up to 3 prior DNA damaging agents or cytotoxic chemotherapy treatments (prior therapies with biologic agents including, IL-2, interferon, vaccines, immunostimulating agents, immune checkpoint inhibitors and signal transduction inhibitors are allowed). Chemotherapy received as adjuvant therapy (with an interval more than 1 year) will not be considered as prior chemotherapy.
  5. Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 to 1.
  6. Adequate hematologic, renal and hepatic function as follows:

    • Absolute Neutrophil Count (ANC) ≥ 1500/μL.
    • Platelet ≥ 100,000/μL.
    • Hemoglobin ≥ 5.6 mmol/L.
    • Serum creatinine ≤ 1.5 upper normal limit of institution's normal ranger OR creatinine clearance ≥ 50 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal.
    • Bilirubin ≤ 1.5 × the upper normal limit of institution's normal range.
    • AST and ALT ≤ 2.5 × the upper normal limit of institution's normal range. For subjects with liver metastases, AST and ALT < 5 × the upper normal limit of institution's normal range.
    • APTT must be ≤ 1.5 × upper normal limit of institution's normal range and International Normalized Ratio (INR) < 1.5. Subjects on anticoagulant (such as Coumadin) will have PTT and INR as determined by the investigator.
    • Serum pregnancy test for women of childbearing potential, including women who have had a tubal ligation; childbearing potential is defined as not having undergone surgical sterilization, hysterectomy, and/or bilateral oophorectomy, or not being postmenopausal (≥ 12 months of amenorrhea).
  7. Females of childbearing potential and men must agree to use adequate contraception (one of the following listed below) prior to study entry, for the duration of study participation and up to 90 days following completion of therapy.
  8. Measurable disease, as defined by standard RECIST v1.1. Previously irradiated lesions should not be counted as target lesions.
  9. Metastatic or locally advanced lesion(s) of which a histological biopsy can safely be obtained according to standard clinical care procedures.
  10. Capable of understanding and complying with parameters as outlined in the protocol and able to sign and date the informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.

Exclusion Criteria:

Both part A and B:

  1. Received any anti-cancer therapy including chemotherapy, immunotherapy, anti-hormonal therapy, radiotherapy, biologic or any investigational therapy within either 28 days, or 5 half-lives of a targeted therapy (whichever is shorter), prior to the first dose of veliparib.

    • For prostate cancer, subjects receiving bisphosphonates are eligible if the subject has been on stable doses of bisphosphonates for the 2 months prior to study initiation without Grade 2 or greater toxicities. For breast cancer patients bisphosphonates are allowed.
    • For prostate cancer, Luteinizing Hormone Releasing Hormone (LHRH) analogue agents are allowed if the subject has received LHRH analogues during the 2 months prior to study initiation.
  2. Has known central nervous system (CNS) metastases, unless treated properly with stable disease (without dexamethasone or with a stable or reducing dose of dexamethason) for at least 3 months prior to study entry.
  3. Patients at high risk for seizure such as uncontrolled seizure disorder or focal or generalized seizure within the last 12 months.
  4. Clinically significant and uncontrolled major medical condition(s) including but not limited to:

    • Active uncontrolled infection.
    • Subject has previous or current malignancies at other sites, with the exception of:

      • Adequately treated in situ carcinoma of the cervix uteri;
      • Basal or squamous cell carcinoma of the skin;
      • Previous malignancy (e.g., localized prostate cancer) confined and surgically resected, treated with chemotherapy or radiation therapy, and is considered cured by the investigator.
    • Symptomatic congestive heart failure.
    • Unstable angina pectoris or cardiac arrhythmia.
    • Psychiatric illness/social situation that would limit compliance with study requirements.
    • QTc with Frederichs correction >470 ms.
    • Any medical condition, which in the opinion of the study investigator places the subject at an unacceptably high risk for toxicities.
  5. Pregnant or breastfeeding female.
  6. Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive veliparib .
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03044795

Contacts
Contact: J. A. Gietema, MD, PhD +31 50 3612821 j.a.gietema@umcg.nl
Contact: M. Jalving, MD, PhD +31 50 361 2821 m.jalving@umcg.nl

Locations
Netherlands
University Medical Center Groningen Not yet recruiting
Groningen, Netherlands, 9713 GZ
Contact: J. A. Gietema, MD, PhD    +31 50 3612821    j.a.gietema@umcg.nl   
Contact: M. Jalving, MD, PhD    +31 50 3612821    m.jalving@umcg.nl   
Principal Investigator: J. A. Gietema, MD, PhD         
Erasmus MC Not yet recruiting
Rotterdam, Netherlands
Contact: A. Jager, MD, PhD    +31 10 7041733    a.jager@erasmusmc.nl   
Principal Investigator: A. Jager, MD, PhD         
Sponsors and Collaborators
University Medical Center Groningen
AbbVie
Dutch Cancer Society
Investigators
Principal Investigator: J. A. Gietema, MD, PhD University Medical Center Groningen
  More Information

Responsible Party: J.A. Gietema, Principal investigator, University Medical Center Groningen
ClinicalTrials.gov Identifier: NCT03044795     History of Changes
Other Study ID Numbers: 201600942
Study First Received: February 2, 2017
Last Updated: June 1, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by J.A. Gietema, University Medical Center Groningen:
homologous recombination deficiency
veliparib
PARP inhibitor
biomarker

Additional relevant MeSH terms:
Veliparib
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents

ClinicalTrials.gov processed this record on August 23, 2017